Abstract:The interactions between polymers and the immune system remains poorly controlled. In some instances, the immune system can produce antibodies specific to polymer constituents. Indeed, roughly half of pe-gloticase patients without immunomodulation develop high titers of anti-PEG antibodies (APA) to the PEG polymers on pegloticase, which then quickly clear the drug from circulation and render the gout treatment ineffective. Here, using pegloticase as a model drug, we show that addition of high molecular weight (MW) free (unconjugated) PEG to pegloticase allows us to control the immunogenicity and mit-igates APA induction in mice. Compared to pegloticase mixed with saline, mice repeatedly dosed with pegloticase containing different MW or amount of free PEG possessed 4-to 12-fold lower anti-PEG IgG, and 6-to 10-fold lower anti-PEG IgM, after 3 rounds of pegloticase dosed every 2 weeks. The markedly reduced APA levels, together with competitive inhibition by free PEG, restored the prolonged circula-tion of pegloticase to levels observed in APA-naive animals. In contrast, mice with pegloticase-induced APA eliminated nearly all pegloticase from the circulation within just four hours post-injection. These re-sults support the growing literature demonstrating free PEG may effectively suppress drug-induced APA, which in turn may offer sustained therapeutic benefits without requiring broad immunomodulation. We also showed free PEG effectively blocked the PEGylated protein from binding with cells expressing PEG-specific B cell receptors. It provides a template of how we may be able to tune the interactions and immunogenicity of other polymer-modified therapeutics. Statement of significance A major challenge with engineering materials for drug delivery is their interactions with the immune system. For instance, our body can produce high levels of anti-PEG antibodies (APA). Unfortunately, the field currently lack tools to limit immunostimulation or overcome pre-existing anti-PEG antibodies, with-out using broad immunosuppression. Here, we showed that simply introducing free PEG into a clinical formulation of PEG-uricase can effectively limit induction of anti-PEG antibodies, and restore their pro-longed circulation upon repeated dosing. Our work offers a readily translatable method to safely and effectively restore the use PEG-drugs in patients with PEG-immunity, and provides a template to use unconjugated polymers with low immunogenicity to regulate interactions with the immune system for other polymer-modified therapeutics. (c) 2023 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

A HISTOCHEMICAL AND ELECTRON MICROSCOPICAL STUDY OF THE FIBRINOID OF THE MOUSE PLACENTA.

The Importance of Poly(ethylene glycol) Alternatives for Overcoming PEG Immunogenicity in Drug Delivery and Bioconjugation

Hydroxy polyethylene glycol: a solution to evade human pre-existing anti-PEG antibodies for efficient delivery

To PEGylate or not to PEGylate: Immunological properties of nanomedicine's most popular component, polyethylene glycol and its alternatives

A Novel Zwitterionic Copolymer with A Short Poly(Methyl Acrylic Acid) Block for Improving Both Conjugation and Separation Efficiency of A Protein Without Losing Its Bioactivity

Therapeutic Protein PEPylation: the Helix of Nonfouling Synthetic Polypeptides Minimizes Antidrug Antibody Generation.

Polyethylene Glycol Immunogenicity: Theoretical, Clinical, and Practical Aspects of Anti-Polyethylene Glycol Antibodies

Pegloticase Co-Administered with High MW Polyethylene Glycol Effectively Reduces PEG-immunogenicity and Restores Prolonged Circulation in Mouse

Poly(ethylene Glycol) Alternatives in Biomedical Applications

Poly(ethyl Ethylene Phosphate): Overcoming the "polyethylene Glycol Dilemma" for Cancer Immunotherapy and Mrna Vaccination.

Long-acting interferon-alpha 2a modified with a trimer-structured polyethylene glycol: preparation, in vitro bioactivity, in vivo stability and pharmacokinetics

Molecular Insights into the Improved Bioactivity of Interferon Conjugates Attached to a Helical Polyglutamate

PEGylated Liposomes for Diagnosis of Polyethylene Glycol Allergy

Ethylene oxide graft copolymers reduce the immunogenicity of lipid nanoparticles

Is body posture relevant for neonatal studies?

Polyethylene Glycol (Peg)-Associated Immune Responses Triggered by Clinically Relevant Lipid Nanoparticles in Rats

Polyethylene Glycol‐Like Brush Polymer Conjugate of a Protein Drug Does Not Induce an Antipolymer Immune Response and Has Enhanced Pharmacokinetics than Its Polyethylene Glycol Counterpart

Anti-PEG Antibodies: Current Situation and Countermeasures

Synthesis and Systematic Study on the Effect of Different PEG Units on Stability of PEGylated, Integrin-αvβ6-Specific A20FMDV2 Analogues in Rat Serum and Human Plasma

Effects of PEG antibodies on in vivo performance of LNP-mRNA vaccines

In vivo metabolism and safety evaluation of PEGylated proteins drugs